title: Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris.
abstract: BACKGROUND
  Recombinant antibodies are highly successful in many different pathological conditions and currently enjoy overwhelming recognition of their potential. There are a wide variety of protein expression systems available, but almost all therapeutic antibodies are produced in mammalian cell lines, which mimic human glycosylation. The production of clinical-grade antibodies in mammalian cells is, however, extremely expensive. Compared to mammalian systems, protein production in yeast strains such as Pichia pastoris, is simpler, faster and usually results in higher yields.
  
  
  RESULTS
  In this work, a trivalent single-chain fragment variable (scFv)-based N-terminal trimerbody, specific for the human carcinoembryonic antigen (CEA), was expressed in human embryonic kidney 293 cells and in Pichia pastoris. Mammalian- and yeast-produced anti-CEA trimerbody molecules display similar functional and structural properties, yet, the yield of trimerbody expressed in P. pastoris is about 20-fold higher than in human cells.
  
  
  CONCLUSIONS
  P. pastoris is an efficient expression system for multivalent trimerbody molecules, suitable for their commercial production.
authors.forename: Ana
authors.initials: A
authors.lastname: Blanco-Toribio
authors.forename: Javier
authors.initials: J
authors.lastname: Lacadena
authors.forename: Natalia
authors.initials: N
authors.lastname: Nuñez-Prado
authors.forename: Ana
authors.initials: A
authors.lastname: Álvarez-Cienfuegos
authors.forename: Maider
authors.initials: M
authors.lastname: Villate
authors.forename: Marta
authors.initials: M
authors.lastname: Compte
authors.forename: Laura
authors.initials: L
authors.lastname: Sanz
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Blanco
authors.forename: Luis
authors.initials: L
authors.lastname: Álvarez-Vallina
mesh_terms: D001709:Biotechnology / Q000379:methods*; D002272:Carcinoembryonic Antigen / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005822:Genetic Vectors; D057809:HEK293 Cells; D006801:Humans; D055767:Immobilized Proteins / Q000378:metabolism; D010843:Pichia / Q000378:metabolism*; D055550:Protein Stability; D017434:Protein Structure, Tertiary; D044967:Serum / Q000378:metabolism; D057127:Single-Chain Antibodies / Q000096:biosynthesis* / Q000737:chemistry* / Q000302:isolation & purification
chemical_list: D002272:Carcinoembryonic Antigen; D055767:Immobilized Proteins; D057127:Single-Chain Antibodies
references.citation: J Immunol Methods. 2012 Jan 31;375(1-2):159-65
references.pmid: 22019510
references.citation: Cancer Gene Ther. 2007 Apr;14(4):380-8
references.pmid: 17218946
references.citation: Nat Biotechnol. 2003 Dec;21(12):1486-92
references.pmid: 14634668
references.citation: Cancer Res. 1996 Jul 1;56(13):3055-61
references.pmid: 8674062
references.citation: Biosci Biotechnol Biochem. 2000 Oct;64(10):2138-44
references.pmid: 11129586
references.citation: J Immunol Methods. 2001 Sep 1;255(1-2):103-14
references.pmid: 11470291
references.citation: Appl Microbiol Biotechnol. 2012 Jan;93(1):31-9
references.pmid: 22057543
references.citation: MAbs. 2011 May-Jun;3(3):289-98
references.pmid: 21487242
references.citation: Appl Microbiol Biotechnol. 2012 Nov;96(4):885-94
references.pmid: 23053101
references.citation: PLoS One. 2013 Jun 28;8(6):e67008
references.pmid: 23840574
references.citation: Methods Mol Biol. 2012;899:157-75
references.pmid: 22735952
references.citation: Cancer Res. 1992 Oct 15;52(20):5647-55
references.pmid: 1382844
references.citation: J Biotechnol. 2009 Feb 23;139(4):318-25
references.pmid: 19162096
references.citation: Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S115-8; discussion S144-51
references.pmid: 18181714
references.citation: Front Immunol. 2013 Jul 29;4:217
references.pmid: 23908655
references.citation: J Microbiol Biotechnol. 2013 May;23(5):587-601
references.pmid: 23648847
references.citation: Trends Biotechnol. 2010 Jul;28(7):355-62
references.pmid: 20447706
references.citation: Acta Pharmacol Sin. 2010 Sep;31(9):1198-207
references.pmid: 20694021
references.citation: Biotechnology (N Y). 1995 Mar;13(3):255-60
references.pmid: 9634767
references.citation: PLoS One. 2009;4(4):e5381
references.pmid: 19401768
references.citation: FEBS J. 2012 Sep;279(17):3022-32
references.pmid: 22748038
references.citation: Bioessays. 2008 Sep;30(9):904-18
references.pmid: 18693269
references.citation: MAbs. 2013 Jan-Feb;5(1):70-9
references.pmid: 23221741
references.citation: FEBS J. 2013 Oct;280(19):4816-26
references.pmid: 23890417
references.citation: Biochemistry. 1992 Feb 18;31(6):1579-84
references.pmid: 1737014
references.citation: MAbs. 2012 Mar-Apr;4(2):226-32
references.pmid: 22453098
references.citation: Bioconjug Chem. 2011 Oct 19;22(10):2014-20
references.pmid: 21866954
references.citation: Biochim Biophys Acta. 2003 May 30;1648(1-2):75-83
references.pmid: 12758149
references.citation: Cancer Immunol Immunother. 2000 Jul;49(4-5):243-52
references.pmid: 10941907
references.citation: Expert Opin Biol Ther. 2008 Aug;8(8):1187-99
references.pmid: 18613770
references.citation: Protein Eng. 1997 Oct;10(10):1221-5
references.pmid: 9488147
references.citation: Protein Eng Des Sel. 2012 Aug;25(8):425-35
references.pmid: 22718791
references.citation: FEMS Microbiol Rev. 2000 Jan;24(1):45-66
references.pmid: 10640598
references.citation: MAbs. 2011 May-Jun;3(3):299-309
references.pmid: 21393992
references.citation: Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8
references.pmid: 8341653
references.citation: J Biochem. 2003 Dec;134(6):911-7
references.pmid: 14769881
references.citation: Methods Mol Biol. 2014;1060:215-43
references.pmid: 24037844
references.citation: Protein J. 2013 Aug;32(6):419-25
references.pmid: 23897421
references.citation: Biotechnol Appl Biochem. 2016 Mar-Apr;63(2):200-5
references.pmid: 24673401
references.citation: Int J Cancer. 2006 Jul 15;119(2):455-62
references.pmid: 16477626